Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Vanda Pharmaceuticals Reports Second Quarter 2009 Results
Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
BenchmarkJournal.Com Free Analyst Review for PNM, WH, NCR, UNT, VNDA and SCMR
Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
Titan Announces FDA Approval of Fanapt™ (Iloperidone) For the Treatment of Schizophrenia
FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia
FDA approves new schizophrenia drug
Vanda Pharmaceuticals Reports First Quarter 2009 Results
New Insights into the Mechanism of Action of Antipsychotic Drugs
Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
Vanda Pharmaceuticals Provides Update on Iloperidone
Vanda Pharmaceuticals Reports Second Quarter 2008 Results
BeaconEquity.com Issues Technical Trade Alerts on Market Movers: ZONS, SSCC, VNDA, DSTI, XOMA, GNVC
Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests - Business Wire
LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests - PR Newswire
Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference - May 27 2008 1:02AM
Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference - Jun 2 2008 2:04AM
Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events - Jun 2 2008 2:04AM
New Analyst Reports for ALBERTA OILSANDS INC, RUBICON MINERALS CORPORATION, ZOLTEK COMPANIES INC, and VANDA PHARMACEUTICALS INC - May 27 2008 1:16AM
Vanda Pharmaceuticals Reports First Quarter 2008 Results - Jun 2 2008 2:03AM
Vanda Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 1, 2008
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
